Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | PHASE1 | COMPLETED | 154 | — | — | Oct 1, 2016 | Apr 1, 2024 | Nov 13, 2024 | 23 | United States, France +2 |
| Arm | Type | Description |
|---|---|---|
| Non-CLL B Cell Malignancies (Group NHL) Part A | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| CLL/SLL (Group CLL) Part A | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part B | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| CLL/SLL (Group CLL) Part B | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion | EXPERIMENTAL | XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Name | Type | Description |
|---|---|---|
| XmAb13676 | BIOLOGICAL | Biological |
Inclusion Criteria: * Able to provide written informed consent * Diagnosis of either Non-CLL B cell malignancy * Ineligible for or have exhausted standard therapeutic options and have relapsed or refractory disease * ECOG performance status 0-2 * Fertile patients must agree to use highly effective ...